Suppr超能文献

长期全基因组血液 RNA 表达谱为复发缓解型多发性硬化症 IFN-β-1b 治疗的新分子反应候选物提供了依据。

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.

机构信息

Department of Neurology, University of Rostock, Gehlsheimer Str. 20, 18047 Rostock, Germany.

出版信息

Pharmacogenomics. 2010 Feb;11(2):147-61. doi: 10.2217/pgs.09.152.

Abstract

AIMS

In multiple sclerosis patients, treatment with recombinant IFN-beta (rIFN-beta) is partially efficient in reducing clinical exacerbations. However, its molecular mechanism of action is still under scrutiny.

MATERIALS & METHODS: We used DNA microarrays (Affymetrix, CA, USA) and peripheral mononuclear blood cells from 25 relapsing remitting multiple sclerosis patients to analyze the longitudinal transcriptional profile within 2 years of rIFN-beta administration. Sets of differentially expressed genes were attained by applying a combination of independent criteria, thereby providing efficient data curation and gene filtering that accounted for technical and biological noise. Gene ontology term-association analysis and scientific literature text mining were used to explore evidence of gene interaction.

RESULTS

Post-therapy initiation, we identified 42 (day 2), 175 (month 1), 103 (month 12) and 108 (month 24) differentially expressed genes. Increased expression of established IFN-beta marker genes, as well as differential expression of circulating IFN-beta-responsive candidate genes, were observed. MS4A1 (CD20), a known target of B-cell depletion therapy, was significantly downregulated after one month. CMPK2, FCER1A, and FFAR2 appeared as hitherto unrecognized multiple sclerosis treatment-related differentially expressed genes that were consistently modulated over time. Overall, 84 interactions between 54 genes were attained, of which two major gene networks were identified at an earlier stage of therapy: the first (n = 15 genes) consisted of mostly known IFN-beta-activated genes, whereas the second (n = 12) mainly contained downregulated genes that to date have not been associated with IFN-beta effects in multiple sclerosis array research.

CONCLUSION

We achieved both a broadening of the knowledge of IFN-beta mechanism-of-action-related constituents and the identification of time-dependent interactions between IFN-beta regulated genes.

摘要

目的

在多发性硬化症患者中,重组干扰素-β(rIFN-β)治疗部分有效,可减少临床恶化。然而,其作用机制仍在研究中。

材料和方法

我们使用 DNA 微阵列(Affymetrix,CA,美国)和 25 例复发缓解型多发性硬化症患者的外周血单核细胞,分析 rIFN-β给药后 2 年内的纵向转录谱。通过应用独立标准的组合获得差异表达基因集,从而提供有效的数据管理和基因过滤,以考虑技术和生物学噪声。使用基因本体论术语关联分析和科学文献文本挖掘来探索基因相互作用的证据。

结果

治疗开始后,我们在第 2 天、第 1 个月、第 12 个月和第 24 个月分别鉴定出 42、175、103 和 108 个差异表达基因。观察到已建立的 IFN-β标记基因的表达增加,以及循环 IFN-β反应性候选基因的差异表达。MS4A1(CD20)是 B 细胞耗竭治疗的已知靶点,在治疗后 1 个月明显下调。CMPK2、FCER1A 和 FFAR2 作为迄今为止尚未被识别的多发性硬化症治疗相关差异表达基因,在整个研究期间持续被调控。总体而言,获得了 54 个基因之间的 84 个相互作用,其中两个主要基因网络在治疗早期被鉴定出来:第一个(n = 15 个基因)主要由已知的 IFN-β激活基因组成,而第二个(n = 12 个)主要包含迄今为止与 IFN-β在多发性硬化症阵列研究中的作用无关的下调基因。

结论

我们既拓宽了 IFN-β作用机制相关成分的知识,又确定了 IFN-β调节基因之间的时间依赖性相互作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验